JUPITER trial (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "JUPITER trial" in English language version.

refsWebsite

Global rank English rank

10nih.gov

4^th place

8doi.org

2^nd place

2endocrinetoday.com

low place

1books.google.com

3^rd place

1brighamandwomens.org

low place

1latimes.com

22^nd place

19^th place

1ahajournals.org

3,608^th place

6,526^th place

1semanticscholar.org

11^th place

8^th place

1reuters.com

49^th place

47^th place

1marketwatch.com

1,303^rd place

808^th place

1ccjm.org

low place

1archives-ouvertes.fr

1,031^st place

879^th place

1nytimes.com

7^th place

ahajournals.org

circoutcomes.ahajournals.org

Paul M Ridker, MD, MPH (May 2009). "The JUPITER Trial: Results, Controversies, and Implications for Prevention". Circulation: Cardiovascular Quality and Outcomes. 2009, 2 (3): 279–285. doi:10.1161/CIRCOUTCOMES.109.868299. PMID 20031849. S2CID 2271425.{{cite journal}}: CS1 maint: multiple names: authors list (link)

archives-ouvertes.fr

hal.archives-ouvertes.fr

de Lorgeril, M (2010). "Cholesterol Lowering, Cardiovascular Diseases, and the Rosuvastatin-JUPITER Controversy: A Critical Reappraisal" (PDF). Arch Intern Med. 170 (12): 1032–1036. doi:10.1001/archinternmed.2010.184. PMID 20585068.

books.google.com

Myat, Aung; Gershlick, A. H.; Gershlick, Tony (2012). Landmark Papers in Cardiovascular Medicine. Oxford University Press. p. 35. ISBN 978-0-19-959476-4.

brighamandwomens.org

JUPITER trial information page, Brigham and Women’s Hospital

ccjm.org

Shishehbor MH, Hazen SL (January 2009). "JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?". Cleve Clin J Med. 76 (1): 37–44. doi:10.3949/ccjm.75a.08105. PMC 2836530. PMID 19122109.

doi.org

Ridker PM; Jupiter Study, Group (November 2003). "Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial". Circulation. 108 (19): 2292–7. doi:10.1161/01.CIR.0000100688.17280.E6. PMID 14609996. {{cite journal}}: |first2= has generic name (help)
Ridker PM, Danielson E, Fonseca FA, et al. (November 2008). "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein". N. Engl. J. Med. 359 (21): 2195–207. doi:10.1056/NEJMoa0807646. PMID 18997196.
Paul M Ridker, MD, MPH (May 2009). "The JUPITER Trial: Results, Controversies, and Implications for Prevention". Circulation: Cardiovascular Quality and Outcomes. 2009, 2 (3): 279–285. doi:10.1161/CIRCOUTCOMES.109.868299. PMID 20031849. S2CID 2271425.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Hlatky MA (November 2008). "Expanding the orbit of primary prevention--moving beyond JUPITER". N. Engl. J. Med. 359 (21): 2280–2. doi:10.1056/NEJMe0808320. PMID 18997195.
Shishehbor MH, Hazen SL (January 2009). "JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?". Cleve Clin J Med. 76 (1): 37–44. doi:10.3949/ccjm.75a.08105. PMC 2836530. PMID 19122109.
Mora S, Musunuru K, Blumenthal RS (February 2009). "The Clinical Utility of High-Sensitivity C-Reactive Protein in Cardiovascular Disease and the Potential Implication of JUPITER on Current Practice Guidelines". Clin. Chem. 55 (2): 219–28. doi:10.1373/clinchem.2008.109728. PMID 19095730.
de Lorgeril, M (2010). "Cholesterol Lowering, Cardiovascular Diseases, and the Rosuvastatin-JUPITER Controversy: A Critical Reappraisal" (PDF). Arch Intern Med. 170 (12): 1032–1036. doi:10.1001/archinternmed.2010.184. PMID 20585068.
Elliott P, et al. (2009). "Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease". JAMA. 302 (1): 37–48. doi:10.1001/jama.2009.954. PMC 2803020. PMID 19567438.

endocrinetoday.com

"JUPITER: Using hsCRP to identify primary prevention patients who may benefit from statin therapy", Endocrine Today, 25 November 2008
"Treating elevated C-reactive protein with a statin", Endocrine Today, 1 December 2008

latimes.com

"To combat plaques, research targets inflammation-fighting statins"^{[dead link‍]}, Los Angeles Times, 8 December 2008

marketwatch.com

"Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows", press release, MarketWatch, 25 November 2008

nih.gov

pubmed.ncbi.nlm.nih.gov

Ridker PM; Jupiter Study, Group (November 2003). "Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial". Circulation. 108 (19): 2292–7. doi:10.1161/01.CIR.0000100688.17280.E6. PMID 14609996. {{cite journal}}: |first2= has generic name (help)
Ridker PM, Danielson E, Fonseca FA, et al. (November 2008). "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein". N. Engl. J. Med. 359 (21): 2195–207. doi:10.1056/NEJMoa0807646. PMID 18997196.
Paul M Ridker, MD, MPH (May 2009). "The JUPITER Trial: Results, Controversies, and Implications for Prevention". Circulation: Cardiovascular Quality and Outcomes. 2009, 2 (3): 279–285. doi:10.1161/CIRCOUTCOMES.109.868299. PMID 20031849. S2CID 2271425.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Hlatky MA (November 2008). "Expanding the orbit of primary prevention--moving beyond JUPITER". N. Engl. J. Med. 359 (21): 2280–2. doi:10.1056/NEJMe0808320. PMID 18997195.
Shishehbor MH, Hazen SL (January 2009). "JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?". Cleve Clin J Med. 76 (1): 37–44. doi:10.3949/ccjm.75a.08105. PMC 2836530. PMID 19122109.
Mora S, Musunuru K, Blumenthal RS (February 2009). "The Clinical Utility of High-Sensitivity C-Reactive Protein in Cardiovascular Disease and the Potential Implication of JUPITER on Current Practice Guidelines". Clin. Chem. 55 (2): 219–28. doi:10.1373/clinchem.2008.109728. PMID 19095730.
de Lorgeril, M (2010). "Cholesterol Lowering, Cardiovascular Diseases, and the Rosuvastatin-JUPITER Controversy: A Critical Reappraisal" (PDF). Arch Intern Med. 170 (12): 1032–1036. doi:10.1001/archinternmed.2010.184. PMID 20585068.
Elliott P, et al. (2009). "Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease". JAMA. 302 (1): 37–48. doi:10.1001/jama.2009.954. PMC 2803020. PMID 19567438.

ncbi.nlm.nih.gov

Shishehbor MH, Hazen SL (January 2009). "JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?". Cleve Clin J Med. 76 (1): 37–44. doi:10.3949/ccjm.75a.08105. PMC 2836530. PMID 19122109.
Elliott P, et al. (2009). "Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease". JAMA. 302 (1): 37–48. doi:10.1001/jama.2009.954. PMC 2803020. PMID 19567438.

nytimes.com

Kolata, Gina (June 30, 2009). "Study Dismisses Protein's Role in Heart Disease". New York Times. Retrieved July 1, 2009.

reuters.com

"Astra's Crestor gets sales boost after positive data", Reuters, 24 November 2008

semanticscholar.org

api.semanticscholar.org

Paul M Ridker, MD, MPH (May 2009). "The JUPITER Trial: Results, Controversies, and Implications for Prevention". Circulation: Cardiovascular Quality and Outcomes. 2009, 2 (3): 279–285. doi:10.1161/CIRCOUTCOMES.109.868299. PMID 20031849. S2CID 2271425.{{cite journal}}: CS1 maint: multiple names: authors list (link)